Pacira BioSciences, Inc. (NASDAQ: PCRX) is a Healthcare company in the Drug Manufacturers - Specialty & Generic industry. QuoTrend tracks its price, financials, earnings, analyst ratings and insider trades.
Latest market price
24.69
+0.21+0.86%
TA
Loading chart...
Snapshot
| Index | - | P/E | 70.12 | EPS (ttm) | 0.35 | Insider Own | 6.97% | Shs Outstand | 39.34M | Perf Week | -2.64% |
| Market Cap | 971.18M | Forward P/E | 7.18 | EPS next Y | 3.44 | Insider Trans | -1.52% | Shs Float | 37.68M | Perf Month | 1.35% |
| Enterprise Value | 1.18B | PEG | 1.08 | EPS next Q | 0.76 | Inst Own | - | Short Float | 19.45% | Perf Quarter | 10.57% |
| Income | 14.57M | P/S | 1.30 | EPS this Y | 725.61% | Inst Trans | - | Short Ratio | 13.37 | Perf Half Y | 9.39% |
| Sales | 746.15M | P/B | 1.45 | EPS next Y | 18.95% | ROA | 1.18% | Short Interest | 7.33M | Perf YTD | -4.60% |
| Book/sh | - | P/C | 5.19 | EPS next 5Y | 10.06% | ROE | 2.13% | 52W High | 27.66 -10.74% | Perf Year | -5.29% |
| Cash/sh | - | P/FCF | 5.41 | EPS past 3/5Y | -22.22% -45.51% | ROIC | 1.35% | 52W Low | 18.80 31.33% | Perf 3Y | -27.91% |
| Dividend Est. | - | EV/EBITDA | 10.26 | Sales past 3/5Y | 2.87% 11.04% | Gross Margin | 79.21% | Volatility | 3.84% 2.86% | Perf 5Y | -55.43% |
| Dividend TTM | - | EV/Sales | 1.58 | EPS Y/Y TTM | 116.28% | Oper. Margin | 2.47% | ATR (14) | 0.79 | Perf 10Y | -40.04% |
| Dividend Ex-Date | - | Quick Ratio | 3.94 | Sales Y/Y TTM | 6.42% | Profit Margin | 1.96% | RSI (14) | 45.43 | Recom | 2.69 |
| Dividend Gr. 3/5Y | - | Current Ratio | 5.04 | EPS Q/Q | -1.35% | SMA20 | -3.09% | Beta | 0.24 | Target Price | 28.75 |
| Payout | 0.00% | Debt/Eq | 0.61 | Sales Q/Q | 6.08% | SMA50 | -2.63% | Rel Volume | 1.14 | Prev Close | 24.48 |
| Employees | 827 | LT Debt/Eq | 0.64 | Earnings | Nov 05 | SMA200 | 3.34% | Avg Volume | 582.58K | Price | 24.69 |
| IPO Date | Feb 03, 2011 | Option/Short | Yes / Yes | EPS/Sales Surpr. | 12.96% 0.70% | Net Debt/EBITDA | 1.80 | Volume | 662,073 | Change | 0.86% |
Analyst Ratings
| Date | Action | Analyst | Rating | Target |
|---|---|---|---|---|
| Sep-09-26 | Initiated | Leerink | Market Perform | $28 |
| Aug-17-26 | Reiterated | Truist Financial | Buy | $25 → $30 |
| Aug-05-26 | Reiterated | RBC Capital | Sector Perform | $25 |
| May-01-26 | Reiterated | Needham | Buy | $63 → $32 |
| Dec-08-25 | Initiated | Barclays | Equal Weight | $24 → $27 |
| Feb-28-25 | Reiterated | Barclays | Overweight | $24 |
| Feb-28-25 | Reiterated | HC Wainwright & Co. | Buy | $57 → $48 |
| Jan-30-25 | Upgrade | Truist Securities | Sell → Hold | $8.00 → $25 |
| Nov-07-24 | Reiterated | Piper Sandler | Overweight | $42 → $12 |
| Sep-24-24 | Reiterated | Jefferies | Buy | $36 → $18 |
Latest News· Times ET
Sep-09-26
Sep-09-2607:21AM
04:00AM
Aug-17-26
Aug-07-26
Aug-07-2609:23PM
04:00AM
Aug-06-26
Aug-06-2604:00AM
Aug-05-26
09:21AM
Aug-04-26
02:41PM
12:01PM
Pacira BioSciences Reports Second Quarter 2026 Financial Resultsglobenewswire.com
Aug-03-26
Aug-03-2601:18AM
Jul-27-26
Jul-27-2604:03AM
04:00AM
Jul-25-26
Jul-25-2609:59PM
Company
Operating within the United States, Pacira BioSciences, Inc. is dedicated to providing healthcare professionals and their patients with non-opioid solutions for pain management and regenerative health. Its offerings include EXPAREL, an injectable liposomal bupivacaine suspension, and ZILRETTA, an extended-release injectable suspension of triamcinolone acetonide. Furthermore, the company offers the iovera system, a non-opioid, handheld cryoanalgesia device capable of delivering precisely controlled cold temperatures to targeted nerves. Pacira also develops its unique multivesicular liposome (MVL) drug delivery technology, which encapsulates therapeutic compounds while preserving their inherent molecular structure. Established in 2006, the firm was formerly known as Pacira Pharmaceuticals, Inc. until its name change to Pacira BioSciences, Inc. in April 2019. Its main corporate office is situated in Tampa, Florida.
Ownership
Per-holder 13F data hasn't been ingested for this ticker yet.
Financial Statements
DataTimeframe
| Line Item (USD, M) | TTM — | FY 2025 12/31/2025 | FY 2024 12/31/2024 | FY 2023 12/31/2023 | FY 2022 12/31/2022 | FY 2021 12/31/2021 | FY 2020 12/31/2020 | FY 2019 12/31/2019 | FY 2018 12/31/2018 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | 746 | 726 | 701 | — | — | — | — | — | — | |
| Cost of Goods Sold Incl. D&A | 154 | 150 | 170 | — | — | — | — | — | — | |
| Gross Profit | 591 | 577 | 531 | — | — | — | — | — | — | |
| Selling, General and Administrative Excl. Other | 380 | 369 | 294 | — | — | — | — | — | — | |
| Research and Development | 121 | 117 | 82 | — | — | — | — | — | — | |
| Other Operating Expense | 71 | 57 | 228 | — | — | — | — | — | — | |
| Operating Income | 18 | 33 | -73 | — | — | — | — | — | — | |
| Interest Expense | 14 | 15 | 17 | — | — | — | — | — | — | |
| Unusual Expense | — | — | — | — | — | — | — | — | — | |
| Non-Operating Income (Expense) | 14 | -2 | 27 | — | — | — | — | — | — | |
| Net Income Before Taxes | 19 | 17 | -63 | — | — | — | — | — | — | |
| Income Taxes | 3 | 10 | 36 | — | — | — | — | — | — | |
| Consolidated Net Income | 15 | 7 | -100 | — | — | — | — | — | — | |
| Net Income From Continuing Operations | 15 | 7 | -100 | — | — | — | — | — | — | |
| Net Income | 15 | 7 | -100 | — | — | — | — | — | — | |
| EPS (Recurring) | 0.35 | 0.16 | -2.15 | — | — | — | — | — | — | |
| EPS (Basic, Before Extraordinaries) | 0.35 | 0.16 | -2.15 | — | — | — | — | — | — | |
| EPS (Diluted) | 0.35 | 0.16 | -2.15 | — | — | — | — | — | — | |
| EBITDA | 115 | 123 | 29 | — | — | — | — | — | — | |
| Other After Tax Adjustments | — | — | — | — | — | — | — | — | — | |
| Stock Option Compensation Expense | — | — | — | — | — | — | — | — | — | |
| Price To Earnings Ratio | 70.54 | 161.75 | — | — | — | — | — | — | — | |
| Price To Sales Ratio | 1.29 | 1.60 | 1.24 | — | — | — | — | — | — | |
| Gross Margin | 79.22 | 79.48 | 75.75 | — | — | — | — | — | — | |
| Operating Margin | 2.41 | 4.55 | -10.41 | — | — | — | — | — | — | |
| Net Margin | 2.01 | 0.96 | -14.27 | — | — | — | — | — | — | |
| Shares Outstanding | 39 | 45 | 46 | — | — | — | — | — | — | |
| Market Capitalization | 963 | 1,165 | 867 | — | — | — | — | — | — | |
| Operating Lease Expense | — | — | — | — | — | — | — | — | — |
Unlock full historical data
See years of past statements with Premium.
Insider Trading Volume
Insider Trading
| Insider | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|
| SLONIN JONATHAN | Chief Medical Officer | Aug 17 '26 | Sale | 23.23 | 3,040 | 70,619 | 216,384 | Aug 18 |
| RIKER LAUREN | Senior Vice President, Finance | Jun 11 '26 | Sale | 23.50 | 6,115 | 143,703 | 62,284 | Jun 12 |
| WILLIAMS KRISTEN | Chief Administrative Officer | Jun 04 '26 | Sale | 22.27 | 10,259 | 228,468 | 167,062 | Jun 05 |
| Cross Shawn | Chief Financial Officer | Apr 23 '26 | Option Exercise | 16.45 | 12,941 | 212,879 | 118,282 | Apr 24 |
| Cross Shawn | Chief Financial Officer | Apr 23 '26 | Sale | 25.16 | 12,941 | 325,596 | 105,341 | Apr 24 |
| Cross Shawn | Chief Financial Officer | Apr 22 '26 | Option Exercise | 16.45 | 1,500 | 24,675 | 106,841 | Apr 22 |
| Cross Shawn | Chief Financial Officer | Apr 22 '26 | Sale | 25.01 | 1,500 | 37,515 | 105,341 | Apr 22 |
| Cross Shawn | Chief Financial Officer | Apr 21 '26 | Option Exercise | 16.45 | 2,845 | 46,800 | 108,186 | Apr 22 |
| Cross Shawn | Chief Financial Officer | Apr 20 '26 | Option Exercise | 16.45 | 7,714 | 126,895 | 113,055 | Apr 22 |
| Cross Shawn | Chief Financial Officer | Apr 20 '26 | Sale | 25.14 | 7,714 | 193,930 | 105,341 | Apr 22 |
| Froimson Mark | Director | Mar 17 '26 | Sale | 21.81 | 500 | 10,905 | 20,136 | Mar 19 |
| SLONIN JONATHAN | Chief Medical Officer | Mar 17 '26 | Sale | 22.82 | 3,261 | 74,416 | 223,640 | Mar 19 |
| WILLIAMS KRISTEN | Chief Administrative Officer | Feb 02 '26 | Sale | 20.53 | 13,137 | 269,703 | 131,303 | Feb 03 |
| RIKER LAUREN | Senior Vice President, Finance | Feb 02 '26 | Sale | 20.81 | 4,000 | 83,240 | 52,313 | Feb 03 |
| RIKER LAUREN | Senior Vice President, Finance | Jan 05 '26 | Sale | 24.24 | 1,416 | 34,324 | 59,064 | Jan 06 |
QuoTrend signals describe historical patterns and statistics — educational information, not investment advice or a recommendation to buy or sell. Past performance doesn’t guarantee future results. Every figure traces to QuoTrend data. Historical patterns — not a prediction or advice.